Biotech Marks Progress on Programs for Cancer, Infectious Diseases

August 16, 2018

By The Life Science Report

Source: Streetwise Reports   08/15/2018

This firm, focused on immuno-oncology and infectious diseases including Ebola and Zika, is moving forward on a variety of fronts, according to a Maxim Group analyst.

In an Aug. 8 research report, analyst Jason McCarthy provided an update on Inovio Pharmaceuticals Inc.’s (INO:NASDAQ) various development programs as the company moves through H2/18.

Its lead candidate, VGX-3100, addressing cancers and precancers attributed to human papillomavirus (HPV), is moving through parallel phase 3 clinical trials. The two studies, REVEAL 1 and REVEAL 2, will each enroll “198 patients with cervical intraepithelial neoplasia (CIN) 2/3 associated with HPV types 16 or 18 across 100 study centers globally,” the analyst stated. Presently 70 sites are open. The expectation is that the trials will read out in 2020, and McCarthy notes that “China is upside; if sites in China are included as part of REVEAL-2, timelines would accelerate.” VGX-3100 is also in phase 2 for vulvar lesions.


Get our Weekly Commitment of Traders Report: - See where the biggest traders (Hedge Funds and Commercial Hedgers) are positioned in the futures markets on a weekly basis.




Get Our Free Metatrader 4 Indicators - Put Our Free MetaTrader 4 Custom Indicators on your charts when you join our Weekly Newsletter






Maxim expects to see data from immuno-oncology studies either later in 2018 or in 2019. These include studies for INO-5401 in glioblastoma, MEDI0457 in head-and-neck cancer and INO-5150 in prostate cancer. INO-5401 is also in development for bladder cancer.

On the infectious disease front, McCarthy noted Inovio has vaccines in development for Zika, Ebola, HIV, MERS and Lassa. Maxim anticipates stockpiling vaccines could begin by 2020. “Pending the outcome of P2 studies of INO-4500 (Lassa) and INO-4700 (MERS) through the partnership with CEPI (Coalition for Epidemic Preparedness Innovations), these two vaccines could ultimately gain government stockpiling contracts and be the first revenue generating vaccines for Inovio,” McCarthy stated.

The analyst also noted the company “has a strong balance sheet,” reporting “2Q18 with revenue of $24.4M (grants, collaborations) and a net loss of $6.6M. The company ended the period with $95.6M in cash on the balance sheet.”

Maxim has a Buy rating on Inovio and a target price of $8 per share. The stock is currently trading at around $4.44.

[NLINSERT]

Disclosure:
1) Tracy Salcedo compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.

Disclosures from Maxim Group, Inovio Pharmaceuticals Inc., August 8, 2018

I, Jason McCarthy, Ph.D., attest that the views expressed in this research report accurately reflect my personal views about the subject security and issuer. Furthermore, no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report.

I, Caroline Palomeque, attest that the views expressed in this research report accurately reflect my personal views about the subject security and issuer. Furthermore, no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report.

The research analyst(s) primarily responsible for the preparation of this research report have received compensation based upon various factors, including the firm’s total revenues, a portion of which is generated by investment banking activities.

Maxim Group makes a market in Inovio Pharmaceuticals Inc.

Maxim Group managed/co-managed/acted as placement agent for an offering of the securities for Inovio Pharmaceuticals Inc. in the past 12 months.

Maxim Group received compensation for investment banking services from Inovio Pharmaceuticals Inc. in the past 12 months.

Maxim Group expects to receive or intends to seek compensation for investment banking services from Inovio Pharmaceuticals Inc. in the next 3 months.

( Companies Mentioned: INO:NASDAQ,
)